• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday

    7/27/22 5:29:38 AM ET
    $AAMC
    $AAN
    $AUPH
    $AYLA
    Real Estate
    Finance
    Diversified Commercial Services
    Consumer Discretionary
    Get the next $AAMC alert in real time by email

    Gainers

    • Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
    • Pagaya Technologies Ltd. (NASDAQ:PGY) jumped 73.1% to close at $16.74. The stock has seen continued volatility after the company completed its SPAC merger agreement last month.
    • Freight Technologies, Inc. (NASDAQ:FRGT) jumped 67.6% to close at $2.48 after the company announced it was awarded Samsung Mexico SDS business and has begun using its platform to assist with effecting Samsung's shipments from Mexico to the United States.
    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) gained 60.8% to settle at $2.75. Comera Life Sciences reported preclinical topline safety results of lead SQore Excipient.
    • InflaRx N.V. (NASDAQ:IFRX) climbed 38.1% to close at $1.92 after the company announced plans to apply for Emergency Use Authorization from the FDA for vilobelimab for the treatment of critically ill COVID-19 patients.
    • Sunshine Biopharma, Inc. (NASDAQ:SBFM) rose 32% to settle at $1.36.
    • HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) gained 30.1% to close at $1.22.
    • Nutriband Inc. (NASDAQ:NTRB) jumped 28.5% to close at $6.53. Nutriband said 1.2 million shares will be cancelled from total outstanding shares following final court judgment in favor of the company.
    • AMTD Digital Inc. (NYSE:HKD) rose 28.4% to settle at $56.31 on continued post-IPO volatility.
    • Greenbrook TMS Inc. (NASDAQ:GBNH) surged 24.6% to close at $2.38.
    • Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) rose 19.9% to settle at $1.69.
    • Versus Systems Inc. (NASDAQ:VS) gained 19.6% to settle at $0.54 after the USPTO issued U.S. Patent No. 11,376,498 to the company to cover games and challenges that produce real world rewards inside of apps and streaming media.
    • Evaxion Biotech A/S (NASDAQ:EVAX) gained 19.3% to close at $3.03. Oppenheimer recently assumed Evaxion Biotech with an Outperform rating and announced a price target of $16.
    • Mustang Bio, Inc. (NASDAQ:MBIO) jumped 18.3% to close at $0.65.
    • Covenant Logistics Group, Inc. (NASDAQ:CVLG) gained 18.1% to settle at $34.51 following better-than-expected Q2 results.
    • Chimerix, Inc. (NASDAQ:CMRX) gained 17.7% to close at $2.40.
    • Code Chain New Continent Limited (NASDAQ:CCNC) rose 17.7% to close at $0.3611 after dropping over 19% on Monday.
    • Zenvia Inc. (NASDAQ:ZENV) surged 17.1% to settle at $2.46.
    • ProKidney Corp. (NASDAQ:PROK) rose 16.1% to close at $11.25.
    • Endo International plc (NASDAQ:ENDP) gained 16.1% to close at $0.5224.
    • Vapotherm, Inc. (NASDAQ:VAPO) jumped 15.5% to settle at $2.38.
    • Venus Concept Inc. (NASDAQ:VERO) rose 15.4% to close at $0.60.
    • Talaris Therapeutics, Inc. (NASDAQ:TALS) gained 15.1% to settle at $4.51.
    • Empire Petroleum Corporation (NYSE:EP) gained 14.7% to close at $10.39.
    • Imperial Petroleum Inc. (NASDAQ:IMPP) rose 14.6% to settle at $0.49.
    • Redbox Entertainment Inc. (NASDAQ:RDBX) rose 14.1% to settle at $6.33.
    • Calix Inc (NYSE:CALX) shares gained 13.7% to close at $50.38 after the company announced upbeat Q2 results and issued strong Q3 sales forecast.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) rose 13.3% to settle at $1.41. Bluejay Diagnostics posted a Q2 loss of $0.10 per share.
    • Encore Wire Corporation (NASDAQ:WIRE) shares jumped 10.5% to close at $122.50 after the company reported Q2 results.
    • Shell Midstream Partners, L.P. (NYSE:SHLX) gained 10.3% to close at $16.05 after the company, and Shell USA, announced the two have reached a definitive merger agreement.
    • Virax Biolabs Group Limited (NASDAQ:VRAX) rose 9.8% to close at $18.44 after the company announced it has launched distribution of Monkeypox and Varicella-Zoster Viruses Real Time PCR Detection Kits in response to the world's major Monkeypox outbreak.
    • TrueBlue, Inc. (NYSE:TBI) gained 7.7% to close at $20.64 following upbeat Q2 earnings.
    • GeoVax Labs, Inc. (NASDAQ:GOVX) gained 6.9% to close at $1.70. GeoVax Labs shares jumped 150% on Monday on news that WHO has declared Monkeypox a public health emergency over the weekend.
    • Altisource Asset Management Corporation (NYSE:AAMC) rose 6.2% to close at $16.46. Altisource Asset Management recently announced it purchased 286,873 shares of its common stock from Putnam Focused Equity Fund at $10 per share.
    • STRATA Skin Sciences, Inc. (NASDAQ:SSKN) rose 4.6% to settle at $1.15 after the company announced U.S. commercial launch of TheraClearX Acne Therapy System.

     

    Losers

    • Revelation Biosciences, Inc. (NASDAQ:REVB) shares dipped 51.4% to close at $0.4910 on Tuesday after the company reported pricing of $5 million public offering. Revelation Biosciences shares jumped 55% on Monday after the company announced the data from its Phase 1b CLEAR clinical study of REVTx-99b met the primary endpoint.
    • Luokung Technology Corp. (NASDAQ:LKCO) fell 41.2% to close at $0.2350 after the company announced an $8 million registered direct offering priced at $0.30 per share.
    • Exela Technologies, Inc. (NASDAQ:XELA) shares fell 36.4% to close at $1.85 amid effectiveness of a 1-for-20 reverse stock split of the company's common stock.
    • Onion Global Limited (NYSE:OG) fell 32.1% to settle at $0.38 in sympathy with Walmart, which cut guidance amid inventory markdowns.
    • Koss Corporation (NASDAQ:KOSS) fell 25.8% to close at $8.31. Koss shares jumped 45% on Monday following a Bloomberg Law report titled "Apple, Koss Reach Deal in AirPods Patent Case on Eve of Trial."
    • Sundial Growers Inc. (NASDAQ:SNDL) fell 23.3% to close at $2.28 following effect of 1:10 reverse stock split.
    • Trinseo PLC (NYSE:TSE) fell 22% to close at $33.52 after the company announced it will pause the sale process of its styrenics business.
    • Cyteir Therapeutics, Inc. (NASDAQ:CYT) dropped 21.9% to settle at $2.71.
    • Coinbase Global, Inc. (NASDAQ:COIN) fell 21.1% to close at $52.93.
    • Vinco Ventures, Inc. (NASDAQ:BBIG) dipped 20.8% to close at $0.7920. Vinco Ventures postponed stockholder meeting from July 26, 2022 to August 23, 2022.
    • Verb Technology Company, Inc. (NASDAQ:VERB) dropped 20.3% to close at $0.6699.
    • JE Cleantech Holdings Limited (NASDAQ:JCSE) fell 19% to close at $1.96.
    • Dermata Therapeutics, Inc. (NASDAQ:DRMA) dropped 18.6% to close at $0.57.
    • Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) dropped 16% to settle at $8.82 after the company received a notice regarding the U.S. Patent Office Patent Trial and Appeal Board's decision to institute trial.
    • BridgeBio Pharma, Inc. (NASDAQ:BBIO) fell 15.8% to settle at $9.29. BridgeBio Pharma announced interim results from PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia, the most common form of short-limbed dwarfism.
    • The Aaron's Company, Inc. (NYSE:AAN) fell 15.3% to close at $13.13 after the company lowered its sales guidance for the full year.
    • MINISO Group Holding Limited (NYSE:MNSO) fell 15% to close at $6.13. Blue Orca Capital issued a short report on MINISO Group.
    • Jaguar Health, Inc. (NASDAQ:JAGX) fell 14.9% to close at $0.2850.
    • Histogen Inc. (NASDAQ:HSTO) dipped 14.7% to settle at $2.67.
    • Airspan Networks Holdings Inc. (NASDAQ:MIMO) fell 14.5% to close at $2.90.
    • Missfresh Limited (NASDAQ:MF) dipped 14.5% to settle at $0.25.
    • Zedge, Inc. (NYSE:ZDGE) fell 14.4% to close at $2.61.
    • Nuvectis Pharma, Inc. (NASDAQ:NVCT) declined 14.3% to settle at $9.54.
    • Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) dipped 14.2% to close at $1.1150. Kaival Brands recently announced the launch of PMI's self-contained e-vapor product, VEEBA, in Canada.
    • Shopify Inc. (NYSE:SHOP) dropped 14.1% to close at $31.55 after the company announced it will lay off 10% of its workforce.
    • Borqs Technologies, Inc. (NASDAQ:BRQS) fell 13.7% to close at $1.20.
    • NextPlay Technologies, Inc. (NASDAQ:NXTP) fell 13.6% to close at $0.2428.
    • Party City Holdco Inc. (NYSE:PRTY) dipped 13.5% to settle at $1.09.
    • SpringBig Holdings, Inc. (NASDAQ:SBIG) dropped 10.6% to close at $1.85.
    • Rent-A-Center, Inc. (NASDAQ:RCII) fell 10.3% to close at $21.09.
    • Cooper-Standard Holdings Inc. (NYSE:CPS) dropped 8.9% to close at $4.52.
    • Walmart Inc. (NYSE:WMT) shares fell 7.6% to close at $121.98 after the company cut guidance for the second quarter and full fiscal year. Walmart said it revised its outlook as a result of pricing actions aimed to improve inventory levels at Walmart and Sam's Club in the U.S. and mix of sales.
    Get the next $AAMC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAMC
    $AAN
    $AUPH
    $AYLA

    CompanyDatePrice TargetRatingAnalyst
    Shopify Inc.
    $SHOP
    2/17/2026$150.00Hold → Buy
    Truist
    Coinbase Global Inc.
    $COIN
    2/12/2026$120.00Buy → Neutral
    Monness Crespi & Hardt
    Shopify Inc.
    $SHOP
    2/12/2026$150.00Neutral → Outperform
    Mizuho
    Shopify Inc.
    $SHOP
    2/12/2026$159.00Hold → Buy
    TD Cowen
    Shopify Inc.
    $SHOP
    2/10/2026$150.00Neutral → Buy
    MoffettNathanson
    Shopify Inc.
    $SHOP
    2/2/2026Neutral → Buy
    Arete
    Coinbase Global Inc.
    $COIN
    1/28/2026$240.00Neutral
    Robert W. Baird
    BridgeBio Pharma Inc.
    $BBIO
    1/28/2026$157.00Overweight
    Barclays
    More analyst ratings

    $AAMC
    $AAN
    $AUPH
    $AYLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Shopify upgraded by Truist with a new price target

    Truist upgraded Shopify from Hold to Buy and set a new price target of $150.00

    2/17/26 8:04:32 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    Coinbase Global downgraded by Monness Crespi & Hardt with a new price target

    Monness Crespi & Hardt downgraded Coinbase Global from Buy to Neutral and set a new price target of $120.00

    2/12/26 7:44:13 AM ET
    $COIN
    Finance: Consumer Services
    Finance

    Shopify upgraded by Mizuho with a new price target

    Mizuho upgraded Shopify from Neutral to Outperform and set a new price target of $150.00

    2/12/26 7:19:59 AM ET
    $SHOP
    Computer Software: Prepackaged Software
    Technology

    $AAMC
    $AAN
    $AUPH
    $AYLA
    SEC Filings

    View All

    SEC Form 6-K filed by Zenvia Inc.

    6-K - Zenvia Inc. (0001836934) (Filer)

    2/18/26 5:01:12 PM ET
    $ZENV
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-K filed by TrueBlue Inc.

    10-K - TrueBlue, Inc. (0000768899) (Filer)

    2/18/26 4:49:47 PM ET
    $TBI
    Professional Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/18/26 4:49:52 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAMC
    $AAN
    $AUPH
    $AYLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kumar Neil converted options into 64,698 shares and covered exercise/tax liability with 30,970 shares, increasing direct ownership by 15% to 262,504 units (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    2/18/26 6:41:47 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Apuli Maricel covered exercise/tax liability with 4,349 shares and sold $37,898 worth of shares (510 units at $74.31), decreasing direct ownership by 4% to 123,945 units (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    2/18/26 6:39:24 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CFO Trimarchi Thomas sold $1,016,147 worth of shares (13,600 units at $74.72) and covered exercise/tax liability with 18,819 shares, decreasing direct ownership by 9% to 336,585 units (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    2/18/26 6:36:26 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAMC
    $AAN
    $AUPH
    $AYLA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for LUPKYNIS

    Submission status for AURINIA PHARMACEUTICALS, INC.'s drug LUPKYNIS (ORIG-1) with active ingredient VOCLOSPORIN has changed to 'Approval' on 01/22/2021. Application Category: NDA, Application Number: 213716, Application Classification: Type 1 - New Molecular Entity

    1/25/21 11:31:10 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAMC
    $AAN
    $AUPH
    $AYLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mulacek Phil E bought $20,363 worth of shares (6,800 units at $2.99), increasing direct ownership by 0.11% to 6,173,732 units (SEC Form 4)

    4 - EMPIRE PETROLEUM CORP (0000887396) (Issuer)

    1/5/26 5:22:42 PM ET
    $EP
    Oil & Gas Production
    Energy

    Director Mulacek Phil E bought $16,353 worth of shares (5,451 units at $3.00), increasing direct ownership by 0.09% to 6,166,932 units (SEC Form 4)

    4 - EMPIRE PETROLEUM CORP (0000887396) (Issuer)

    12/31/25 5:21:46 PM ET
    $EP
    Oil & Gas Production
    Energy

    Director Jin David bought $238 worth of shares (247 units at $0.96), increasing direct ownership by 633% to 286 units (SEC Form 4)

    4 - MUSTANG BIO, INC. (0001680048) (Issuer)

    12/30/25 4:15:14 PM ET
    $MBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAMC
    $AAN
    $AUPH
    $AYLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26, 2026. Aurinia's management team will host a webcast and conference call on February 26, 2026, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-8029 / +1 201-689-8029. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Com

    2/19/26 6:00:00 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ZENVIA receives Nasdaq notification regarding minimum bid price deficiency

    SÃO PAULO, Feb. 18, 2026 /PRNewswire/ -- Zenvia Inc. (the "Company") received today a written notice (the "Notice") from the Listing Qualifications Department of  The Nasdaq Stock Market LLC ("Nasdaq") indicating that, based upon the closing bid price of the Company's Class A common shares (the "Securities") for the 30 previous consecutive business days, it no longer met Nasdaq's minimum bid price requirement of US$1 per share (the "Minimum Bid Price Requirement"), as set forth by Nasdaq Listing Rules 5550(a)(2) and 5810(c)(3)(A). This current report is filed pursuant to Nasdaq Listing Rule 5810(b). The Notice has no immediate effect on the listing of the Securities, which continue to trade 

    2/18/26 7:44:00 PM ET
    $ZENV
    Computer Software: Prepackaged Software
    Technology

    TrueBlue Reports Fourth Quarter and Full-Year 2025 Results

    TrueBlue (NYSE:TBI) today announced its fourth quarter and full-year results for 2025. Fourth Quarter 2025 Financial Highlights Revenue of $418 million, up 8 percent compared to the prior year period $14 million of revenue from the January 2025 HSP acquisition Net loss of $32 million compared to net loss of $12 million in the prior year period Includes non-cash impairment charge of $18 million on right-of-use and long-lived assets associated with the Chicago support center sublease SG&A expense improved 11 percent to $95 million compared to $107 million in the prior year period Adjusted EBITDA1 of $2 million compared to $9 million in the prior year period Cash of

    2/18/26 4:05:00 PM ET
    $TBI
    Professional Services
    Consumer Discretionary

    $AAMC
    $AAN
    $AUPH
    $AYLA
    Leadership Updates

    Live Leadership Updates

    View All

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Walmart names Shishir Mehrotra to Board of Directors

    Walmart Inc. (NASDAQ:WMT) announced the appointment of Shishir Mehrotra, Chief Executive Officer at Superhuman (formerly Grammarly), to the company's Board of Directors, effective today. He will serve on the Board's Compensation and Management Development Committee and the Technology and eCommerce Committee. "Our focus remains on serving customers through a people-led, tech-powered approach," said Greg Penner, chairman of Walmart's Board of Directors. "Shishir's background adds to our boardroom the insight of a proven builder, offering a distinguished track record scaling platforms relied upon by millions." Randall Stephenson, lead independent director, added: "Shishir brings a rare com

    1/8/26 8:02:00 AM ET
    $WMT
    Department/Specialty Retail Stores
    Consumer Discretionary

    La Rosa Holdings Corp. Announces Appointment of Nicholas Adler as Chairman of the Board and Chairman of the Compensation Committee

    Celebration, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) ("La Rosa" or the "Company"), a real estate and PropTech company, today announced that the Company's Board of Directors (the "Board") has appointed Mr. Nicholas Adler as a member of the Board, effective December 29, 2025. Upon his appointment, Mr. Adler was also named Chairman of the Board, Chairman of the Compensation Committee, and a member of both the Audit Committee and the Nominating and Corporate Governance Committee. Additionally, on December 29, 2025, Mr. Siamack Alavi notified the Board of his resignation as a director of the Company, effective immediately. Mr. Alavi also stepped down from hi

    12/30/25 8:30:00 AM ET
    $FRGT
    $LRHC
    Professional Services
    Consumer Discretionary
    Real Estate
    Finance

    $AAMC
    $AAN
    $AUPH
    $AYLA
    Financials

    Live finance-specific insights

    View All

    Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced that it will report financial results for the three and twelve months ended December 31, 2025, and provide an update on recent business progress on February 26, 2026. Aurinia's management team will host a webcast and conference call on February 26, 2026, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-8029 / +1 201-689-8029. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Com

    2/19/26 6:00:00 AM ET
    $AUPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET

    PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its fourth quarter and full year 2025 financial results and business updates after the market closes on Tuesday, February 24, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentat

    2/17/26 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cooper Standard Reports Strong Fourth Quarter Cash Flow Despite Industry Disruption; Continued Margin Expansion and Positive Cash Flow Highlight Full Year 2025 Results

    NORTHVILLE, Mich., Feb. 12, 2026 /PRNewswire/ -- Cooper-Standard Holdings Inc. (NYSE:CPS) today reported results for the fourth quarter and full year 2025. Fourth Quarter 2025 Summary Sales totaled $672.4 million, an increase of 1.8% vs. the fourth quarter of 2024Operating income totaled $0.6 million, a decrease of $31.1 million vs. the fourth quarter of 2024Net income of $3.3 million, or $0.18 per diluted share, reflected a decrease of $36.9 million vs. the fourth quarter of 2024Adjusted EBITDA totaled $34.9 million, or 5.2% of salesNet cash provided by operating activities o

    2/12/26 4:30:00 PM ET
    $CPS
    Auto Parts:O.E.M.
    Consumer Discretionary

    $AAMC
    $AAN
    $AUPH
    $AYLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Trinseo PLC

    SC 13G - Trinseo PLC (0001519061) (Subject)

    12/17/24 5:11:10 PM ET
    $TSE
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13D/A filed by Kaival Brands Innovations Group Inc.

    SC 13D/A - Kaival Brands Innovations Group, Inc. (0001762239) (Subject)

    12/12/24 7:22:30 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Exela Technologies Inc.

    SC 13D/A - Exela Technologies, Inc. (0001620179) (Subject)

    12/3/24 4:01:40 PM ET
    $XELA
    Business Services
    Consumer Discretionary